BACKGROUND: Ketamine, the NMDA glutamate receptor antagonist drug, is increasingly employed as an experimental model of psychosis in healthy volunteers. At subanesthetic doses, it safely and reversibly causes delusion-like ideas, amotivation and perceptual disruptions reminiscent of the aberrant salience experiences that characterize first-episode psychosis. However, auditory verbal hallucinations, a hallmark symptom of schizophrenia, have not been reported consistently in healthy volunteers even at high doses of ketamine. SAMPLING AND METHODS: Here we present data from a set of healthy participants who received moderately dosed, placebo-controlled ketamine infusions in the reduced stimulation environment of the magnetic resonance imaging (MRI) scanner. We highlight the phenomenological experiences of 3 participants who experienced particularly vivid hallucinations. RESULTS: Participants in this series reported auditory verbal and musical hallucinations at a ketamine dose that does not induce auditory hallucination outside of the scanner. CONCLUSIONS: We interpret the observation of ketamine-induced auditory verbal hallucinations in the context of the reduced perceptual environment of the MRI scanner and offer an explanation grounded in predictive coding models of perception and psychosis - the brain fills in expected perceptual inputs, and it does so more in situations of altered perceptual input. The altered perceptual input of the MRI scanner creates a mismatch between top-down perceptual expectations and the heightened bottom-up signals induced by ketamine. Such circumstances induce aberrant percepts, including musical and auditory verbal hallucinations. We suggest that these circumstances might represent a useful experimental model of auditory verbal hallucinations and highlight the impact of ambient sensory stimuli on psychopathology.
BACKGROUND:Ketamine, the NMDAglutamate receptor antagonist drug, is increasingly employed as an experimental model of psychosis in healthy volunteers. At subanesthetic doses, it safely and reversibly causes delusion-like ideas, amotivation and perceptual disruptions reminiscent of the aberrant salience experiences that characterize first-episode psychosis. However, auditory verbal hallucinations, a hallmark symptom of schizophrenia, have not been reported consistently in healthy volunteers even at high doses of ketamine. SAMPLING AND METHODS: Here we present data from a set of healthy participants who received moderately dosed, placebo-controlled ketamine infusions in the reduced stimulation environment of the magnetic resonance imaging (MRI) scanner. We highlight the phenomenological experiences of 3 participants who experienced particularly vivid hallucinations. RESULTS:Participants in this series reported auditory verbal and musical hallucinations at a ketamine dose that does not induce auditory hallucination outside of the scanner. CONCLUSIONS: We interpret the observation of ketamine-induced auditory verbal hallucinations in the context of the reduced perceptual environment of the MRI scanner and offer an explanation grounded in predictive coding models of perception and psychosis - the brain fills in expected perceptual inputs, and it does so more in situations of altered perceptual input. The altered perceptual input of the MRI scanner creates a mismatch between top-down perceptual expectations and the heightened bottom-up signals induced by ketamine. Such circumstances induce aberrant percepts, including musical and auditory verbal hallucinations. We suggest that these circumstances might represent a useful experimental model of auditory verbal hallucinations and highlight the impact of ambient sensory stimuli on psychopathology.
Authors: E Gouzoulis-Mayfrank; K Heekeren; A Neukirch; M Stoll; C Stock; M Obradovic; K-A Kovar Journal: Pharmacopsychiatry Date: 2005-11 Impact factor: 5.788
Authors: Cynthia H Y Fu; Kathryn M Abel; Matthew P G Allin; David Gasston; Sergi G Costafreda; John Suckling; Steve C R Williams; Philip K McGuire Journal: Psychopharmacology (Berl) Date: 2005-10-22 Impact factor: 4.530
Authors: Garry D Honey; Philip R Corlett; Anthony R Absalom; Michael Lee; Edith Pomarol-Clotet; Graham K Murray; Peter J McKenna; Edward T Bullmore; David K Menon; Paul C Fletcher Journal: J Neurosci Date: 2008-06-18 Impact factor: 6.167
Authors: E Pomarol-Clotet; G D Honey; G K Murray; P R Corlett; A R Absalom; M Lee; P J McKenna; E T Bullmore; P C Fletcher Journal: Br J Psychiatry Date: 2006-08 Impact factor: 9.319
Authors: Edward B Perry; Joyce A Cramer; Hyun-Sang Cho; Ismene L Petrakis; Laurence P Karper; Angelina Genovese; Elizabeth O'Donnell; John H Krystal; D Cyril D'Souza Journal: Psychopharmacology (Berl) Date: 2007-02-16 Impact factor: 4.415
Authors: Philip R Corlett; Guillermo Horga; Paul C Fletcher; Ben Alderson-Day; Katharina Schmack; Albert R Powers Journal: Trends Cogn Sci Date: 2018-12-21 Impact factor: 20.229
Authors: Ingeborg H Hansen; Claus Agerskov; Lars Arvastson; Jesper F Bastlund; Helge B D Sørensen; Kjartan F Herrik Journal: Eur J Neurosci Date: 2019-04-01 Impact factor: 3.386
Authors: Renaud Jardri; Kenneth Hugdahl; Matthew Hughes; Jérôme Brunelin; Flavie Waters; Ben Alderson-Day; Dave Smailes; Philipp Sterzer; Philip R Corlett; Pantelis Leptourgos; Martin Debbané; Arnaud Cachia; Sophie Denève Journal: Schizophr Bull Date: 2016-06-03 Impact factor: 9.306
Authors: Stephanie Thiebes; Saskia Steinmann; Stjepan Curic; Nenad Polomac; Christina Andreou; Iris-Carola Eichler; Lars Eichler; Christian Zöllner; Jürgen Gallinat; Gregor Leicht; Christoph Mulert Journal: Neuropsychopharmacology Date: 2018-02-05 Impact factor: 7.853
Authors: P E Vlisides; T Bel-Bahar; A Nelson; K Chilton; E Smith; E Janke; V Tarnal; P Picton; R E Harris; G A Mashour Journal: Br J Anaesth Date: 2018-04-13 Impact factor: 9.166